| 0 (0%) | 09-27 14:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.29 | 1-year : | 9.29 |
| Resists | First : | 7.95 | Second : | 7.96 |
| Pivot price | 7.94 | |||
| Supports | First : | 7.94 | Second : | 6.61 |
| MAs | MA(5) : | 7.94 | MA(20) : | 7.94 |
| MA(100) : | 7.94 | MA(250) : | 8  |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 34.5 | |||
| 52-week | High : | 8.17 | Low : | 7.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JCO ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 7.98 - 8.02 | 8.02 - 8.05 |
| Low: | 7.84 - 7.89 | 7.89 - 7.94 |
| Close: | 7.87 - 7.96 | 7.96 - 8.02 |
Wed, 17 Sep 2025
Space Force cell explores reorg to push commercial data to military - Breaking Defense
Tue, 15 Apr 2025
Lt. Gen. Schiess discusses critical role of CIC, JCO commercial capabilities at 40th Space Symposium - spaceforce.mil
Wed, 22 Jan 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer | Journal of Clinical Oncology - ASCO Publications
Tue, 07 Jan 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology - ASCO Publications
Fri, 13 Dec 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 - ASCO Publications
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 28 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 13.7 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-01-31 |
| Ex-Dividend Date | 2022-01-12 |
|
|
|
|
|
|
|
|
|